Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme

By sjmartinez • June 13, 2023

Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, Palac H, Dilley D, Liu J, Strengholt S, Burmester G. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023 Jun 12:ard-2023-223916. doi: 10.1136/ard-2023-223916. Epub ahead of print. PMID: 37308218.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, methotrexate, Publications, Rheumatology, tumor necrosis factor inhibitors

Related Posts

GLP-1 and Dual GLP-1/GIP Receptor Agonists in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis

Ahmed M, Burhan M, Shafiq A, Hashmi TM, Ahmed R, Fudim M, Mentz RJ, Fonarow GC. GLP-1 and Dual GLP-1/GIP Receptor Agonists in Heart Failure[...]

Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients: MANIFEST-US

Turagam MK, Aryana A, Day JD, Dukkipati SR, Hounshell T, Nair D, Natale A, Weiner S, Cheung JW, Chinitz L, Cuoco F, Daccarett M, Dandamudi[...]

Preliminary insights into methylation patterns in Agent Orange exposed thyroid cancers: a pilot study

Amreen B, Lesseur C, Sadikki H, Saul SR, Kazi S, Leung AM, Nguyen EY, Monaghan M, Taioli E, Genden EM, Chen J, van Gerwen M.[...]